Our Focus on Immuno-Oncology
In the field of immuno-oncology, the STAM™ mouse is the most pathologically suitable model for developing new therapeutic drugs for liver cancer.
The utilization of STAM™ mouse enables non-clinical research for the development of liver cancer therapeutics targeting immune cells, tumor microenvironment, and genetic mutations.
NEWS RELEASE
Initiation of Collaborative Development of a Primary Human Hepatocellular Carcinoma Model and Launch of Collaborative Marketing Activities with PhoenixBio Co., Ltd
February 19, 2026 SMC Laboratories, Inc. (“SMC”) today announced the initiation of a collaborative development…
EVENT
Participation in Digital Partnering
We will be participating in Digital Partnering, a global virtual partnering event for the life sciences indust…
Stem Cell Res Ther.
MicroRNA-4516 in extracellular vesicles-derived mesenchymal stem cells suppressed integrin αV-mediated lung fibrosis ( doi: 10.1186/s13287-025-04559-0.)
CDAHFD Model
The CDAHFD model is a widely used and well-characterized model for the evaluation of pharmacological efficacy of new treatments against liver inflammation, liver fibrosis and fatty liver diseases such as MASLD (formerly: NAFLD).
